Search

Your search keyword '"Kelsen David"' showing total 936 results

Search Constraints

Start Over You searched for: Author "Kelsen David" Remove constraint Author: "Kelsen David"
936 results on '"Kelsen David"'

Search Results

1. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

2. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

4. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

5. Colitis-Associated Cancers

6. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.

7. Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.

9. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

11. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients

12. Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers

14. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

15. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

16. Assessment of the Feasibility of Hyperpolarized [1‐13C]pyruvate Whole‐Abdomen MRI using D2O Solvation in Humans

17. Assessment of the Feasibility of Hyperpolarized [1‐13C]pyruvate Whole‐Abdomen MRI using D2O Solvation in Humans.

18. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

20. Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.

21. Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

22. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages

23. Comprehensive molecular characterization of gastric adenocarcinoma

24. Optimization of ultracentrifugation‐based method to enhance the purity and proteomic profiling depth of plasma‐derived extracellular vesicles and particles.

26. Pilot study of rapid MR pancreas screening for patients with BRCA mutation

27. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

28. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

30. Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer

32. Perioperative versus total neoadjuvant chemotherapy in gastric cancer

33. Tumour extracellular vesicles and particles induce liver metabolic dysfunction

35. Tumour extracellular vesicles and particles induce liver metabolic dysfunction

36. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

37. Supplementary Figure Legends from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

38. Figure S1 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

39. Supplementary Figure Legends from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

40. Figure S2 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

41. Data from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

42. Supplementary Tables S1-S10 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

43. Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

44. Supplementary Figure from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

45. Supplementary Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

46. Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

47. Supplementary Data from A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

48. Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer

49. Supplementary Figure Legends from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

50. Supplementary Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

Catalog

Books, media, physical & digital resources